Breakdown | |||||
TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
345.12B | 343.07B | 341.99B | 351.79B | 293.83B | 302.41B | Gross Profit |
106.45B | 108.14B | 99.52B | 90.78B | 95.41B | 95.15B | EBIT |
29.77B | 29.97B | 25.64B | 14.34B | 24.54B | 30.92B | EBITDA |
46.78B | 51.92B | 44.96B | 37.07B | 49.32B | 50.24B | Net Income Common Stockholders |
22.76B | 23.39B | 17.75B | 9.36B | 28.00B | 24.53B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
69.64B | 75.54B | 48.68B | 68.08B | 83.12B | 83.68B | Total Assets |
477.41B | 476.21B | 457.36B | 478.34B | 433.21B | 386.79B | Total Debt |
110.96B | 110.69B | 105.78B | 142.45B | 109.22B | 98.44B | Net Debt |
41.95B | 35.15B | 57.10B | 74.37B | 26.10B | 14.76B | Total Liabilities |
207.32B | 202.34B | 197.41B | 236.74B | 200.29B | 181.53B | Stockholders Equity |
257.21B | 261.56B | 249.26B | 229.45B | 224.50B | 198.56B |
Cash Flow | Free Cash Flow | ||||
1.26B | 29.77B | 24.24B | -43.72B | -5.90B | 19.51B | Operating Cash Flow |
8.58B | 52.37B | 55.83B | -11.80B | 25.99B | 43.31B | Investing Cash Flow |
-8.07B | -23.48B | -30.41B | -33.76B | -33.80B | -19.28B | Financing Cash Flow |
-7.29B | -1.11B | -46.51B | 30.15B | 5.12B | -22.53B |
Tokuyama Corporation has announced updates on its management strategies to improve capital cost awareness and stock price performance. Despite growth in business performance and stock price, the company’s price book-value ratio remains below 1x, prompting efforts to transform its business portfolio. Key initiatives include enhancing shareholder returns, prioritizing investments in growth businesses, and discontinuing underperforming operations. The company aims to exceed a PBR of 1x and achieve sustainable growth, aligning with its Medium-Term Management Plan 2025.
Tokuyama Corporation reported an increase in both net sales and operating profit for fiscal 2024, driven by strong sales of semiconductor-related products and cost reductions. Despite not meeting all targets of their Medium-Term Management Plan 2025, the company forecasts record highs in net sales, operating profit, and ordinary profit for FY2025. Additionally, Tokuyama plans to enhance shareholder returns by increasing dividends, with a year-end dividend of ¥50 per share for FY2024 and a planned ¥60 per share for FY2025, marking a ¥20 increase for two consecutive periods.
Tokuyama Corporation announced its acquisition of JSR Corporation’s in vitro diagnostics and pharmaceutical materials businesses, aiming to enhance its healthcare domain. This strategic move is expected to accelerate product development, generate synergies, and expand market reach in Japan, Korea, and China, positioning Tokuyama as a significant player in the healthcare industry.
Tokuyama Corporation announced changes in its leadership, with Fumiaki Iwasaki being nominated as the new Representative Director, effective June 24, 2025. This change is part of a new management system aimed at enhancing the company’s strategic direction and operational efficiency. The transition is expected to impact the company’s focus on life sciences, new business development, and environmental safety, potentially strengthening its market position and stakeholder relations.